NCT02213575View on ClinicalTrials.gov

Study 3: Minocycline Decreases Microglia Activation

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 5, 2016

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Hypertension
Interventions
DRUG

Minocycline

Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and 26 week follow-up MRI and PET scans for changes in the paraventricular nucleus.

Trial Locations (1)

32610

UF Health Cardiovascular Clinic, Gainesville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Florida

OTHER

NCT02213575 - Study 3: Minocycline Decreases Microglia Activation | Biotech Hunter | Biotech Hunter